Evitria has entered into an agreement with mAbsolve that will allow the company to use mAbsolve’s gene silencing technology in its antibody cells.
evitria, a Chinese hamster ovary (CHO) transient expression service provider, announced that it has entered into a licensing agreement with mAbsolve, a biotechnology company, on March 10, 2022. The agreement will grant evitria the access to mAbsolve’s gene silencing technology for use in their antibody cells.
Under the terms of the agreement, evitria will provide its customers with antibodies bearing STR silencing modifications, which customers can then use in their experiments without the need to obtain additional R&D licenses. These customers will also have access to technical support and business certainty from mAbsolve.
“We are excited to add STR technology to our antibody engineering and modification capabilities,” said Christian Eberle, CEO of evitria, in a company press release. “STR has been shown to outperform all other modifications to generate truly silent Fc domains and fits perfectly with our state-of-the-art approach at evitria.”
“We look forward to putting STR in the hands of more researchers,” mAbsolve CEO Geoff Hale said in the press release. “evitria’s focus on high-quality CHO expression means they are perfectly positioned to bring our technology to the therapeutic market, and we look forward to supporting their customers with this technology.”
Source: evitria SA